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Surnrnm'y 
The transcription factor E2F is regulated uring the cell cycle through interactions with the 
product of the retinoblastoma susceptibility gene and related proteins. It is thought hat E2F- 
mediated gene regulation at the G1/S boundary and during S phase may be one of the rate- 
limiting steps in cell proliferation. It was reported that in vivo overexpression f  E2F-1 in fi- 
hroblasts induces S phase entry and leads to apoptosis. This observation suggests that E2F plays 
a role in both cell cycle regulation and apoptosis. To further understand the role of E2F in cell 
cycle progression, cell death, and tumor development, we have blocked endogenous E2F ac- 
tivity in HBL-100 cells, derived from nonmalignant human breast epithelium, using dominant- 
negative mutants under the control of a tetracycline-dependent expression system. We have 
shown here that induction of dominant-negative mutants led to strong downregulation ftran- 
siently transfected E2F-dependent chloramphenicol acetyl transferase r porter constructs and of 
endogenous c-myc, which has been described as a target gene of the transcription factor E2F/ 
DP. In addition, we have shown that blocking of  E2F could et~iciendy protect from apoptosis 
induced by serum starvation within a period of 10 d, whereas control cells started to die after 
24 h. Surprisingly, blocking of E2F did not alter the rate of proliferation or of DNA synthesis 
of these cells; this finding indicates that ceil-cycle progression could be driven in an E2F-inde- 
pendent manner. In addition, we have been able to show that blocking of endogenous E2F in 
HBL-100 cells led to rapid induction of tumor growth in severe combined immunodeficiency 
mice. No tumor growth could be observed in mice that received mock-transfected clones or 
tetracycline toblock expression of the E2F mutant constructs in vivo. Thus, it appears that E2F 
has a potential tumor-suppressive function under ce~ain circumstances. Furthermore, we pro- 
vide evidence that dysregulation fapoptosis may be an important step in tumorigenesis. 
A Poptosis and cell cycle are closely hnked and tightly regulated processes that control tissue development, 
differentiation, and homeostasis (1). It is well established 
that deregulated xpression and altered function of the genes 
involved in cell cycle regulation contribute to the patho- 
genesis of cancer (2). In the past few years, evidence accu- 
mulated that resistance toward apoptosis i  another impor- 
tant factor for tumor development (3). This has originally 
been shown in the case of B cell malignancies (3-5). One 
important regulator ofapoptosis  the bd-2 oncogene, which 
was identified at t(14; 18) chromosomal translocation break- 
The first wo authors contributed qually to this work. 
points in the majority of follicular B cell lymphomas. These 
translocations lead to juxtaposition of the bd-2 gene on 
chromosome 18, with the Ig heavy chain gene on chromo- 
some 14. Subsequent overexpression f the bd-2 gene renders 
the lymphoma cells resistant to apoptosis. Thus dysregula- 
tion of apoptosis may be a causative vent in the evolution 
of B cell malignancies. 
The tumor suppressor gene p53 exerts its tumor-sup- 
pressing function by regulating both cell cycle and apopto- 
sis. Induction ofapoptosis by p53 is at least in part due to its 
ability to regulate transcription of members of the bcl-2 gene 
family (6--8). Recently, we have shown that the death-pro- 
moting gene bax, another member of the bd-2 gene family, 
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is strongly downregulated in breast cancer tissue (9). Thus, 
dysregulation of apoptosis might be not only an important 
step in the development of lymphoma but also in the de- 
velopment of solid tumors. 
Apoptosis may sustain tissue homeostasis by balancing 
the effects of  proliferation. The regulatory coupling of  pro- 
liferation and apoptosis is suggested by several recent find- 
ings. A line of investigation relevant o this hypothesis has 
focused on features hared by the pathways ofapoptosis and 
proliferation. These studies have revealed that entry into S 
phase, an initial step in cell cycle progression, may also oc- 
cur in the pathway of cell death (10). One such study of 
prostate epithelial cells showed that apoptosis induced by 
testosterone withdrawal is preceded by reentry into the cell 
cycle: after receiving a stimulus that induces apoptosis, qui- 
escent prostate epithelial ceils enter S phase and then die 
without completing the ceil cycle. A second line of  investi- 
gation has focused on regulatory genes that control both 
proliferation and apoptosis. Expression of  genes important 
for cell cycle regulation, including cydin D, c-myc, Rb, and 
p53, is associated not only with proliferation, but also with 
cell death (6, 11-13). E2F-1, the first member of the family 
of E2F transcription factors, is thought o play a critical role 
in G1/S progression of the cell cycle (14-16). E2F usually 
appears to function to control the transcription of  a group 
of  genes that encode proteins important for cell cycle pro- 
gression during S phase; these proteins include dihydro- 
folate reductase, thymidine kinase, and DNA polymerase ot 
(14). Transcriptional ctivities of E2F are modulated uring 
the ceil cycle, mainly by the formation of complexes be- 
tween E2F and several key regulators of cell cycle such as 
the retinoblastoma protein and related proteins (17-22). 
E2F-1 can form a heterodimer with another E2F-like pro- 
tien DP-1 and have a synergistic effect on its transcriptional 
activity (23, 24). Recently, it has been shown that artificial 
overexpression of exogenous E2F-1 in fibroblasts promotes 
S phase entry and subsequently eads to apoptosis (25-28). 
It was the aim of  this study to examine the role of  E2F/ 
DP1 in apoptosis and cell cycle regulation. Using the tetra- 
cycline-dependent expression system, we established ceil 
lines containing inducible dominant-negative DP-1 or 
E2F-2 mutants. Our major findings are that (1) downregu- 
lation of endogenous E2F/DP activity does not affect the 
proliferation rate in the breast epithelial cell line HBL-100 
but (2) leads to downregulation ofc-myc expression, (3) en- 
hanced resistance to apoptosis, and (4) induction of tumor- 
igenic growth in severe combined immunodeficiency 
(SCID) 1 mice. 
Materials and Methods 
Cells and Culture Conditions. HBL-100 cells were originally iso- 
lated from breast milk of an apparently healthy woman (9). Cells 
were maintained in RPMI 1640 (Seromed-Biochrom, Hamburg, 
1Abbreviations u ed in this paper: CAT, chloramphenicol acetyl transferase; 
EMSA, electrophoretic mobility shift assay; GTC, guanidium isothiocyan- 
ate; RT, reverse transcription; SCID, severe combined immunodeficiency. 
Germany), 10% heat-inactivated FCS, 2 mM L-glutamine (GIBCO, 
Karlsruhe, Germany) and penicillin--streptomycin (Seromed-Bio- 
chrom, Hamburg, Germany). 
Preparation of mRNA and Reverse Transcription-PCR (RT-PCR). 
RNA preparation was performed using the guanidium isothiocy- 
anate (GTC)/CsC1 method. Briefly, cells or tissue were lysed 
with GTC solution (4 M GTC, 20 mM sodium acetate, pH 5.2, 
0.1 mM dithiothreitol, 0.5% Sarcosyl (Sigma Chemical Co., Griin- 
wald, Germany). The resulting GTC-cell lysate was layered on 
top of a CsC1 cushion (5.7 M, 100 mM EDTA). After ultracen- 
trifugation at 150,000 g for 23 h at 18~ the RNA pellet was re- 
suspended in Tris-EDTA (Tris, 10 re_M; EDTA, 5 raM, pH 7.4) 
and precipitated by 3 M sodium acetate and ethanol at -80~ for 
30 man. Total RNA was extracted from cells and tissues as de- 
scribed above. Purification ofpoly(A +) RNA from 10 btg of total 
RNA was performed using the Dynabead mRNA purification kit 
(Dynal, Oslo, Norway). Detection of mRNA by PCR was per- 
formed as described, using a Geneamp RNA PCR kit (Perkin- 
Elmer Cetus, Uberlingen, Germany) and a thermocycler (Bach- 
hofer, Reutlingen, Germany), according to the PCR protocol. 
DP-1, ADP-1, and AE2F-2 PCR products were sequenced and 
subsequently cloned into pUHD-3 and pKEX expression plas- 
mids (see below). The following primers were used for amplifica- 
tion: ADP-I: 5' primer, 5'-CCGGAATTCCGGATGGCAAAA- 
GATGCCGGT-3'; 3' primer, 5'-CGCGGATCCGCGCTATTA- 
CAGGTTCTTGAAGGCAAT-3'; AE2F-2: 5' primer, 5'-CCG- 
GAATTCCGGATGCTGCAAGGGCCCCGG-3'; 3' primer, 
5 ' -CGCGGATCCGCGCTATTACAGAGAGCAGCTCTG-  
GAT-3'; DP-I: 5' primer, 5'-CCGGAATTCCGGATGGCA- 
AAAGATGCCGGT-3'; 3' primer, 5'-CGCGGATCCGCTCAG- 
TCGTCCTCGTC-3' .  
To analyze inducible AE2F-2, ADP-1, or DP-1 expression, 
RT-PCR was performed using an upstream primer from the 5' 
transcribed region of the expression plasmid pUHD-3 (5'-CAG- 
ATCGCCTGGAGACGCC-3'; this procedure resulted in frag- 
ment lengths of 784, 790, and 1,315 bp, respectively). [3-actin was 
amplified using the following primers: upstream, 5'-GAGCTG- 
CGTGTGGCTCCCGAGG-3';  downstream, 5'-CGCAGG- 
ATGGCATGGGGGAGGGCATACCCC-3' (resulting fragment 
length, 246 bp). 
Stable Cell Line HBL- IO0 Expressing Inducible ADp-1 or AE2F-2. 
In the first step, the plasmid pUHD 15-1 (29) containing the tet- 
racycline repressor gene (tet) fused with the viral VP16 coding re- 
gion was linearized with ScaI, cotransfected with the resistance 
plasmAd pUC18 (puromycin resistance; Boehringer Mannheim, 
Mannheim, Germany), and selected for stable HBL-100 cell lines. 
Truncated ADp-1 or AE2F-2 c-DNA contained the DNA 
binding and dimerization domain of DP-1 (1-235 aa) or E2F-2 
(1-233 aa) but were devoid of the NH2-terminal transactivation 
domain (23, 30--32). Constructs were derived from RT-PCR, se- 
quenced, and cloned into the expression plasmid pUHD 10-3 (29). 
This plasmid was cotransfected with the resistance plasmid pKEX 
(33) (hygromycin resistance) in a second step into the stable cell lines. 
Modulation of ADp-1 or AE2F-2 expression was induced by 
incubating the cells in medium in the presence (2 Ixg/ml) or ab- 
sence of tetracycline. In addition, full-length DP-I clones (1-410 
aa) and mock transfectants containing no insert in pUHD 10-3 
were generated by the same protocol. Furthermore, using the ex- 
pression plasmid pKEX, we selected HBL-100 clones, which ex- 
pressed ADp-1 constitutively (ADp-lc). 
Electrophoretic Mobility Shift Assay (EMSA). Preparation of nu- 
clear extracts and EMSAs were performed as described (34, 35). 
Briefly, 2.5 p~g of nuclear extract was incubated with 1 ~g ofpoly 
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(deoxyinosine-deoxycytidine) (poly [dI-dC]) for 20 rain on ice 
and 32p-labeled ouble-stranded oligonucleotides containing a
binding site for E2F/DP (5 ' -ATTTAAGTTTCGCGCCCT-  
TTCTCAA-3')  and subsequently analyzed by native PAGE. 
pH]Thymidine Incorporation Assay. 5 • 104 cells/well were cul- 
tured in medium in 96-well round-bottom plates at 37~ for 72 h. 
The cells were pulsed with 1 p~Ci of [3H]Thymidine (Amersham, 
Braunschweig, Germany) after 3 d of culture, and DNA synthesis 
was measured uring the last 16 h of culture. The cells were har- 
vested onto glass filters, and the incorporated radioactivity was 
measured using a TopCount counter (Canberra Packard, Frank- 
furt, Germany). 
Chloramphenicol Acetyl Transferase (CAT) Assay. CAT assays 
were performed using a reporter plasmid E2F4CAT containing 
the CAT gene under the control of an E2F-dependent promoter 
(36). Transfection with 20 p~g of superhelical reporter plasmid 
DNA per 106 cells in 9-mm culture dishes was carried out by the 
calcium phosphate coprecipitation technique as described previ- 
ously (37). At 48 h after transfection, cellular proteins were ex- 
tracted by a freeze-thaw procedure, and the CAT activity was 
determined as described previously (37). 
Immunocytology. Immunoperoxidase staining of HBL-100 cells 
was performed using the Vecta stain ABC kit (Vector Laborato- 
ries, Burlingame, CA), according to the manufacturer's protocol. 
Anti-c-myc mAb was purchased from Dianova (Hamburg, Ger- 
many); anti-PCNA mouse mAb was purchased from Oncogene 
Science (Cambridge, MA). Polyclonal anti-Ki-67 rabbit serum 
was purchased from Dako (Hamburg, Germany). 
Determination f Apoptotic Cells by Acridine Orange Staining. 
Cells were cultured as described above. Apoptosis was induced by 
serum depletion. After induction ofapoptosis, cultures were seeded 
at 3 • 105 cells per 1-ml tissue culture well in RPMI 1640, stained 
with acridine orange (5 Ixg/ml), and observed by fluorescence mi- 
croscopy. The number of  fragmented nuclei, which reliably indi- 
cates apoptosis, was determined. 
DNA Fragmentation Assay. For DNA fragmentation a alysis, 
cell lysates were obtained by incubating a cell pellet containing 
10 ~ cells in 20 ml oflysis buffer (10 mM EDTA, 50 mM Tris, pH 
8, 0.5% sarcosyl, 0.5 mg/ml proteinase K) for 1 h at 50~ After 
addition of 5 ml of RNase (1 mg/ml) and another incubation for 
1 h at 50~ lysates were electrophoresed on a 2% agarose gel 
containing ethidium bromide. The gel was run in a buffer con- 
raining 26 M Na/HPO 4, 33 mM NaH2PO4, 10 mM EDTA; it 
was photographed under UV illumination. 
Xenotransplantation of Cells into SCID Mice. HBL-100 cells (106) 
were injected subcutaneously into C.B.-17 scid/scid mice. The 
mice were obtained from our own breeding colony and were 
kept in isolators under stringent conditions in the central animal 
laboratory of the Max Delbriick Center for Molecular Medicine. 
Microbiological controls were performed regularly by addition of 
sterile sentinel animals to the colony. Tumors were measured in 
millimeters in two dimensions, length (a) and width (b), using cali- 
pets. Tumor volume (V) was calculated according to V = ab2/2, 
where a is the longer of the two measurements. To repress ADP-1 
expression i  vivo, the drinking water was replaced with 2.5% su- 
crose containing 1.0 mg/ml tetracycline hydrochloride (Sigma 
Chemical Co., St. Louis, MO) as described previously (38). 
Results and Discussion 
Truncated DP-1 and E2F-2 Constructs Block Endogenous 
E2F/DP Activity. To downregnlate endogenous E2F /DP  
activity, we designed DP-1 and E2F-2 mutants (ADP-1 
and AE2F-2) that may act in a dominant-negat ive manner  
to functionally inactivate ndogenous E2F activities. Both 
constructs, ADP-1 and AE2F-2, contained DNA-b ind ing  
domains but  were devoid of  the transactivation domain 
(23, 30-32). By use of a tetracycline-control led expression 
system, the constructs were expressed in HBL-100 cells (a 
nontumor igenic  permanent  cell line) derived from nonma-  
l ignant human breast epithelium. Withdrawal o f  tetracy- 
cline led to the induct ion of  ADP-1 or ~E2F-2  mRNA 
expression which was shown by RT-PCR (Fig. 1 a). The 
upstream primer was chosen from the 5' transcribed region 
of  the expression plasmid to discriminate between exoge- 
nous and endogenous ADP-1 or AE2F-2. We monitored 
the induct ion of  ADP-1 and AE2F-2 by EMSAs and found 
that both ADP-1 and AE2F-2 competed for DNA b inding 
with the endogenous E2F /DP-1  heterodimer (Fig. 1 b). 
Tetracycline withdrawal led to complete disappearance of
the endogenous E2F /DP  b inding complex, which was re- 
Figure 1, Inducible expression of ADP-1 or AE2F-2 in HBL-100 cells. 
(a) Stable clones, which are under transcriptional control of a tetracycline 
(tet)-dependent transactivator, were generated, as described in Materials 
and Methods. HBL-100 clones transfected with either truncated DP-1 
(ZIDP-1), truncated E2F-2 (AE2F-2), or full-length DP-1 (DP-I) were 
analyzed by RT-PCK. The upstream primer was chosen from the 5' 
transcribed region of the expression plasmid to discriminate betw en ex- 
ogenous and endogenous DP-1. The resulting fragment lengths are indi- 
cated. Cells were cultured in the presence (+) or absence (-) of tetracy- 
cline. RNA was extracted 24 h after tetracycline withdrawal. Induction of 
ADP-1, AE2F-2, and DP-1 expression can be detected after tetracycline 
withdrawal, whereas in the presence of tetracycline, expression i  com- 
pletely repressed. 13-Actin and mock transfectants served as controls. (b) 
Nuclear E2F/DP-binding complexes of inducible and constitutive HBL- 
100 clones. The same clones as in a and one constitutive ADP-1 clone 
(ADP-lc) were analyzed byEMSA. Where indicated, a 50-M excess of 
unlabeled binding oligonucleotide was added to show specificity of 
DNA-binding complexes. Cells were cultured in the presence (+) or ab- 
sence (-) of tetracycline. Nuclear protein was extracted 24 h after tetra- 
cycline withdrawal. Induction of ADP-1 or AE2F-2 expression leads to 
complete disappearance of the endogenous E2F/DP binding complex, 
which is replaced by a smaller complex. Full-length DP-1 and mock 
transfectants served as controls. 
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placed by a faster-migrating complex that most likely con- 
tained the truncated mutants. To test whether truncated 
DP-1 or truncated E2F-2 inhibits E2F-dependent  tran- 
scriptional activity, we transfected reporter genes under  the 
control of  an E2F-dependent  promoter  into ADP-1 and 
AE2F-2 clones of HBL-100. As depicted in Fig. 2 a, strongly 
decreased CAT activity could be observed after induct ion 
of  either ADP-1 or AE2F-2. 
Using immunocytological  staining, we were also able to 
show that induct ion of  ADp l  led to strong downregulat ion 
of  endogenous c-myc (Fig. 2 b), which contains E2F-b ind-  
ing sites in its promoter and has been described as a target 
gene of  E2F /DP  (39). The same result was observed using 
the E2F-2 mutant  (not shown). Expression of  Ki-67, a 
marker indicating that the cycling state of  cells, was not  af- 
fected by the induct ion of  ADp-1 (Fig. 2 b). Thus, t run-  
cated DP-1 or E2F-2 blocked E2F /DP-dependent  tran- 
scriptional activity, which was consistent with the complete 
disappearance of endogenous E2F7DP binding complex in 
EMSAs (see Fig. 1). From these results, we conclude that 
our truncated constructs are dominant-negat ive mutants 
that are able to block E2F/DP.  
Blocking of Endogenous E2F/DP Activity Does Not Alter the 
Proliferation Rate of HBL-IO0 Cells. E2F is thought to act 
Figure 2. Downregulation of E2F-dependent promoter activity in 
ADP-1 or AE2F-2 expressing HBL-100 cells. (a) Repression of CAT ac- 
tivity. Transcriptional activity of endogenous E2F was analyzed in induc- 
ible HBL-100 clones, u ing a reporter construct under the control f an 
E2F-dependent promoter. Cells were cultured in the presence (+) or ab- 
sence (-) of tetracycline. CAT assays were performed 24 h after tetracy- 
cline withdrawal, sdescribed in Materials and Methods. Induction of 
ADP-1 or AE2F-2 expression leads to strong downregulation of E2F- 
dependent promoter activity. Induction of full-length DP-1 does not alter 
CAT activity. Mock transfectants served as controls. (b) Downregulation 
of endogenous c-myc expression. Expression of endogenous c-myc protein 
was analyzed in inducible ADP-1 clones by immunocytology, as de- 
scribed in Materials and Methods. Where indicated, cells were cultured in 
the presence (+) or absence (-) of tetracycline. Cells were fixed and 
stained with an indirect immunoperoxidase method 24 h after tetracycline 
withdrawal. Induction of ADP-1 expression leads to strong downregula- 
tion of c-myc expression i HBL-100 cells, whereas expression of Ki-67 
remained unaffected in these cells. Mock transfectants served as control. 
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at the G1/S boundary and during S phase of  the cell cycle. 
E2F-mediated transcriptional ctivation includes genes that 
are important for S phase progression; therefore, E2F may 
be one of  the rate-limiting steps in cell proliferation. For 
this reason, we were interested to find out whether expres- 
sion of  the dominant-negative E2F/DP mutants would in- 
fluence proliferation and DNA synthesis. Surprisingly, block- 
ing of  E2F did not alter the proliferation rate or the DNA 
synthesis rate of  HBL-100 cells (Fig. 3). These results are in 
contrast o the biological effect of  similar dominant-nega- 
tive E2F mutants described in quiescent 3T3 fibroblasts 
(40). In these cells, a AE2F mutant blocked cell cycle pro- 
gression induced by the adenovirus protein E1A. E IA  acts 
via the E2F pathway by liberating E2F from multicompo- 
nent complexes that contain the product of  the retinoblas- 
toma gene, pRb, and related proteins. In the fibroblasts, cell 
cycle progression is E2F-dependent and could therefore be 
blocked by E2F dominant-negative mutants. Although we 
can not exclude the possibility that unaffected cell cycle 
progression in HBL-100 cells expressing either ADP-1 or 
AE2F-2 could be due to incomplete suppression of  endog- 
enous E2F activity, we propose that cell cycle progression 
and transcription of  important S phase genes could be driven 
in an E2F-independent manner. This hypothesis supported 
by our observation that PCNA, an important cell cycle regu- 
lating S phase protein, which is another potential target gene 
of  E2F, was not affected by our dominant-negative mutants 
(not shown). Therefore, it seems that some (naturally oc- 
curring) E2F-responsive promoters can be downregulated 
(c-myc) by such mutants but others cannot be (PCNA). 
Blocking of Endogenous E2F/DP Activity Inhibits Induction 
of Apoptosis. Next we wanted to know whether blocking 
of  endogenous E2F alters sensitivity toward apoptosis. We 
therefore induced apoptosis by serum depletion and asked 
whether the expression of  either ADP-1 or AE2F-2 would 
affect apoptosis. Our results show that after induction of  
ADP-1 or AE2F-2, apoptosis could be blocked for 10 d 
(Fig. 4). In contrast, in the presence of tetracychne, our 
Figure 3. Proliferation rate of ADP-1- or AE2F-2-expressing HBL-100 cells. Cells were cultured in the presence (+) or absence (-) of tetracycline. 
(a and b) Number of viable cells was determined on days 1, 2, 4, 8, and 10 after withdrawal of tetracycline. Viability was determined bytrypan blue stain- 
ing. Mean values and SD of four independently performed exp riments are indicated. (c) [3H]Thymidine incorporation was measured 3 d after with- 
drawal of tetracycline. Again, mean values and SD of four independently performed experiments are indicated. Mock transfectants served as the control. 
Induction of ADP-1 or AE2F-2 expression i  HBL-IO0 cells has no effect on the rate of DNA synthesis or cell proliferation. 
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mock-transfected cell clones started to die via apoptosis af- 
ter 1 d of  serum starvation. Therefore, it appears that in- 
duction of  apoptosis by growth factor depletion in cycling 
ceils was at least in part mediated by an E2F-dependent 
pathway. This concept is in accord with previous findings 
that in vivo overexpression f  exogenous E2F-1 induced 
apoptosis in fibroblasts (25-28). It has been shown that 
constitutive c-myc expression causes apoptosis in serum- 
starved cells (11). We have shown that blocking of  endoge- 
nous E2F led to downregulation of  endogenous c-myc ex- 
pression and inhibition of  apoptosis. Therefore, one might 
speculate that E2F-dependent apoptosis could be regulated 
at least in part by transcription of  the c-myc gene. Our find- 
ings are strengthened by the fact that the retinoblastoma 
gene product, an important regulator of  E2F, also inhibits 
apoptosis (13). 
Thus, E2F/DP is a transcription factor involved in the 
regulation of two different biological processes and there- 
fore provides another example of the close linkage between 
apoptosis and control of the cell cycle. 
Blocking of Endogenous E2F/DP Activity in Normal Breast 
Epithelial Cell Line HBL-I O0 Induces Tumor Growth in SCID 
Mice. We recently provided evidence that dysregulation 
of  apoptosis might be an important step in the pathogenesis 
of  breast cancer (9). Therefore, we were interested in de- 
termining whether enhanced resistance to apoptosis of  
Figure 4. Inhibition of serum starvation-induced apoptosis in ADP-1 or AE2F-2 expressing HBL-100 cells. Cells of soluble ADP-1 or &E2F-2 clones 
or constitutive ADP-1 clones (ADP-lc) were cultured in the presence or absence of tetracycline (+/ -  Tet) for prolonged time periods after serum star- 
vation. (a and b) Apoptosis was assayed morphologically b staining the nuclei with acridine orange on days 1-10. The number of fragmented nuclei (in- 
dicating apoptosis) from 100 cells was determined and is expressed as a percentage ofapoptotic cells. The mean SD of four independent experiments is in- 
dicated. Induction of ADP-1 or AE2F-2 efficiently protects from apoptosis in HBL-100 cells within the observed period of 10 d. In contrast, repression 
of either ADP-1 or AE2F-2 expression led to induction of apoptosis after serum starvation for 2 d. In constitutively expressing cells, tetracycline has no 
effect on apoptosis resistance. Inducible full-length DP-l-expressing cells (DP-I) served as control. (c) Detection of apoptosis by DNA fragmentation in 
ADP-l-expressing HBL-100 cells. Agarose gel electrophoresis of DNA extracted from constitutive or inducible ADP-1 clones 2 d after serum depletion. 
DNA fragmentation can be observed only when ADP-1 expression is repressed. No DNA fragmentation can be observed in ADP-l-expressing cells. 
1210 Apoptosis Inhibition in SCID Mice 
ADP-1 or AE2F-2 expressing cells would induce tumorge- 
nicity. We transplanted ADP-1 and mock-transfected HBL- 
100 cells into SCID mice. To suppress ADP-1 or AE2F-2 
expression in vivo, tetracycline was added to the animals' 
drinking water. As depicted in Fig. 5, tumor growth was 
observed only in animals that carried either ADP-1 -  or 
AE2F-2-expressing cells and obtained no tetracycline from 
their drinking water. No tumor growth was observed in 
animals that were challenged with HBL-100 cells but that 
did not express truncated mutants. Therefore, we conclude 
that blocking of  endogenous E2F activity can induce tumor 
growth in SCID mice and that this induction is most likely 
due to an enhanced resistance to apoptosis. It appears that, 
in cells proliferating in an E2F-independent manner, E2F 
has a potential tumor-suppressive function. Recently, it has 
been reported that induction of  apoptosis in E2F-overex- 
pressing cells depends on the expression of  p53 (27, 28). 
Therefore, it will be interesting to look for loss of  function 
mutations of  the E2F /DP family, particularly in p53- 
expressing tumors. Thus, we provide further evidence that 
dysregulation of  apoptosis is an important step in tumori-  
genesis. 
In conclusion, we found that downregulation of  endog- 
enous E2F/DP activity did not affect the proliferation rate 
of  the breast epithelial cell line HBL-100 but led to down- 
regulation of  c-myc expression, enhanced resistance toward 
apoptosis, and induction of  tumorigenic growth in SCID 
mice. Therefore, we propose the following three hypoth- 
eses. First, cell cycle progression can be driven in an 
E2F independent manner. Second, endogenous E2F is in- 
volved in the regulation of  apoptosis (possibly via tran- 
scriptional regulation of  c-myc expression). Third, under 
certain circumstances, E2F has a potential tumor-suppres- 
sive function. 
a 
2500- 
E 
9 15oo- 
E -I 
0 
=. 1000-  
0 
E 
1- 
500"  
b 
2000 
1500 - 
E 
Q 
E 
1000- B 
O 
~ 500-  
I-- 
0 
0 
= = 
8 12  16  20  24  28  32  36  40  44  48  52  
days 
T 
• 
8 12 16 20 24 28 
days 
1211 Bargou et al. 
16 
........ O- ...... 
z~DP-lc +Tet 
---- ADP-lc -Tet 
t~DP-1 -Tet 
,L ADP-1 +Tet 
AE2F-2 -Tet 
AE2F-2 +Tel 
Figure 5. Tumor growth of ADP-1- or AE2F- 
2-expressing HLB-100 cells in SCID mice. 
Shown is tumor growth of inducible (a) ADP-1, 
(b) AE2F-2, or constitutive ADP-l-expressing (a)
ADP-lc HBL-100 clones in SCID mice. Ammals 
were challenged with the same cell number (106); 
where indicated, tetracycline (1 mg/ml) was 
added to the drinking water to suppress ADP-1 
expression i vivo. Mean values and SD of the 
tumor size of 10 animals are indicated. Expression 
of ADP-1 or AE2F-2 leads to rapid induction of 
tumor growth, whereas tetracycline r pression of
the mutants prevents tumor growth. Since tetra- 
cycline does not affect umor growth of constitu- 
tively expressing clones, suppression of tumor 
growth of inducible clones is not due to a toxic 
effect of tetracycline. Animals challenged with 
mock-transfected or nontransfected clones did 
not show tumor growth (not shown). 
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